This observational pilot study (n=10) will examine salivary oxytocin levels during a single dose of LSD as part of psychedelic-assisted psychotherapy (PAP) for anxiety disorders or depression.
Primary objective is to obtain preliminary data on salivary oxytocin reactivity during a single clinical LSD intake administered as part of PAP for refractory anxiety or depression under compassionate-use authorisation.
No interference with routine clinical care: four saliva samples will be collected on the day of dosing and participants will complete routine self-report questionnaires; participants are selected from consecutive patients in the Addiction Department.
Single clinical-dose LSD administered as part of routine psychedelic-assisted psychotherapy with saliva sampling for oxytocin.
Single LSD dose given in clinical routine (dose per treating team); four saliva samples collected on dosing day.